Clinical Study of Oral PI3K/mTOR Inhibitor in Patients With Advanced Refractory Solid Tumors
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Anthony El-Khoueiry, MD
University of Southern California
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
4 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Medanta Duke Research Institute (mdri)
Gurgaon, Haryana, India
- Central India Cancer Research Institute
Nagpur, Maharashtra, India
- Meenakshi Mission Hospital & Research Centre
Madurai, Tamil Nadu, India
- Usc Norris Comprehensive Cancer Center
Los Angeles, California, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 30 Sept 2012
- Primary completion
- 30 Nov 2015
- Completion
- 31 Mar 2016
- Last update posted
- 29 Sept 2014
- Registered enrollment
- 60
- Registry id
- NCT01762410
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.